Kobe University researchers reported preclinical evidence that mass-producible iPSC-derived allogeneic gamma delta T cells suppressed colorectal cancer tumors in mouse xenograft models, as published in Stem Cell Reports. The approach aims to address the cost and time burden of autologous cell collection and manufacturing. Lead author Takashi Aoi, Ph.D., and colleagues generated an allogeneic iPSC platform using gamma delta (γδ) T cells intended to work across patients with less need for patient-specific tailoring. The team reported an approximate 80,000-fold multiplication in their workflow and demonstrated antitumor activity against patient-derived colorectal cancer tissues implanted into mice. The authors noted that CAR-T therapies show limited efficacy in solid tumors and that their modality leverages MHC-unrestricted targeting, with γδ T cells comprising roughly 3–5% of peripheral blood lymphocytes. While still early, the study supports continued exploration of scalable, off-the-shelf immune cell products for solid-tumor immunotherapy—especially for heterogeneous cancers like CRC.